Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: Impact of FDG PET/CT

Liver International

Volumn 33, Issue 7, 2013, Pages 1085-1091

  Hiraoka, Atsushi ^a   Hirooka, Masashi ^b   Ochi, Hironori ^b   Koizumi, Yohei ^b   Shimizu, Yuko ^a   Shiraishi, Akiko ^a   Yamago, Hiroka ^a   Tanihira, Tetsuya ^a   Miyata, Hideki ^a   Ninomiya, Tomoyuki ^a   Kawasaki, Hideki ^a   Ishimaru, Yoshihiro ^a   Sogabe, Ichiro ^a   Inoue, Takeshi ^a   Abe, Masanori ^b   Hiasa, Yoichi ^b   Matsuura, Bunzo ^b   Onji, Morikazu ^b   Michitaka, Kojiro ^a  

^a EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Positron emission tomography and computed tomography; Synchronous neoplasm

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ARTICLE; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; COLON ADENOMA; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CANCER; PHARYNX CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PROSTATE CANCER; STOMACH CANCER; SUBDURAL HEMATOMA; THYROID ADENOMA; THYROID CANCER; TONGUE CANCER; UTERUS CANCER;

HEPATOCELLULAR CARCINOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SYNCHRONOUS NEOPLASM;

CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; STATISTICS, NONPARAMETRIC;

EID: 84880161388     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12161     Document Type: Article

References (32)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
2. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004; 127: 248-60.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
4. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
5. Ikai I, Arii S, Kojiro M, et al. Reevaluation of Prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
6. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
7. Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol 2010; 25: 403-7.
8. Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990; 5: 616-26.
9. Shiina S, Teratani T, Obi S, et al. Percutaneous ethanol injection therapy for liver tumors. Eur J Ultrasound 2001; 13: 95-106.
10. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
11. Hiraoka A, Horiike N, Yamashita Y, et al. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization. Hepato Gastroenterol 2009; 56: 213-7.
12. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12: 828-9.
13. Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and statistical study. Am J Cancer 1932; 16: 1358-64.
14. Takayasu K, Kasugi H, Ikeya S, et al. A clinical and radiologic study of primary liver cancer associated with extrahepatic primary cancer. Cancer 1992; 69: 45-51.
15. Nzeako UC, Goodman ZD, Ishak KG. Association of hepatocellular carcinoma in north American patients with extrahepatic primary malignancies. Cancer 1994; 74: 2765-71.
16. Shimada M, Takenaka K, Fujiwara Y, et al. Characteristics of hepatocellular carcinoma associated with extrahepatic primary malignancies in southern Japan. Am J Gastroenterol 1996; 91: 754-8.
17. Wong LL, Lurie F, Takanishi DM. Other primary neoplasms in patients with hepatocellular cancer: prognostic implications? Hawaii Med J 2007; 66: 204-8.
18. Fernández-Ruiz M, Guerra-Vales JM, Casterlbón-Fernández FJ, et al. Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of hospital-based tumor registry. J Gastroenterol Hepatol 2009; 24: 1424-30.
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
20. Sobin L, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumors, 7th ed. Hoboken, NJ: John Wiley & Sons, Inc., 2009.
21. Liver cancer study group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Bunkyo-ku, Tokyo: Kanehara, 2009;24.
22. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
23. Stalker LK, Philips RB, Pemberton J. Multiple primary malignant lesions. Surg Gynec Obstet 1939; 68: 595-602.
24. Hajdu SI, Hajdu EO. Multiple primary malignant tumors. J Am Geriatr Soc 1968; 16: 16-26.
25. Moertel CG. Multiple primary malignant neoplasms: introduction and presentation of data. Recent Results Cancer Res 1966; 7: 1-21.
26. Choi JY, Lee KS, Kwan OJ, et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron-emission tomography and computed tomography for initial tumor staging. J Clin Oncol 2005; 23: 7654-9.
27. Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignanct tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230: 417-22.
28. Riesz T, Riskó Z, Winkler V, Juhász J. A clinico-pathological study on the correlation of immunosupresion and multiple primary malignant neoplasms. Neoplasma 1976; 23: 409-20.
29. Teefey SA, Hildeboldt CC, Gehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226: 533-42.
30. Yasuda S, Ide M, Fujii H, et al. Application of positron-emission tomography imaging to cancer screening. Br J Cancer 2000; 83: 1607-11.
31. Koide N, Hanazaki K, Fujimori Y, et al. Synchronous gastric cancer associated with hepatocellular carcinoma: a study of 10 patients. Hepato Gastroenterol 1999; 46: 3008-14.
32. Morita M, Kuwano H, Toh Y, Matsuda H, Matsumata T. The clinical characteristics of patients with synchronous squamous cell carcinoma of the esophagus and hepatocellular carcinoma. Surg Today 1994; 24: 803-8.